若生智能
Drug Database
BR

bronchitis vaccine

✓ Approved

China National Pharmaceutical · 细胞治疗 · 细胞治疗

什么是 bronchitis vaccine？

bronchitis vaccine 是一种细胞治疗，由China National Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司China National Pharmaceutical
药物类别细胞治疗, 疫苗
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, China National Pharmaceutical

治疗适应症

bronchitis vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersBronchitis chronic✓ Approved

相关研究文献

PubMedDigital health2026-08-08

Artificial intelligence in digital mental health technology: Considerations for regulation.

Pais Sarah S, Coole Holly H, Alagarajah Janagan J, Bergin Aislinn Gómez AG

Artificial intelligence (AI) is being introduced into all aspects of life with notable adoption seen in health care and systems and growing utility in the domain of digital mental health technology (DMHT). The Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence in the UK are together exploring the regulation and evaluation of DMHT through a Wellcome-funded project. As part of this initiative, a symposium was held to bring together experts from across the AI and DMHT sector representing a breadth of disciplines, to share insights and inform the project. This review presents a reflection of the key opportunities and challenges of AI in DMHT with a focus on medical device regulation, distilling the main themes from the symposium. To facilitate responsible and agile regulation enabling access to high quality, safe, and effective medical products, regulators will need to continually adapt and develop, with new processes, guidance, initiatives and forums to fully engage in this innovative, exponentially developing field.

PMID 42568722
阅读全文 →
PubMedJournal of fish diseases2026-08-08

Immunogenicity and Protective Efficacy of the First Autogenous Aeromonas hydrophila Vaccine for Piaractus brachypomus.

Pereira Layana Aparecida Batista LAB, do Nascimento Ferreira Juliana J, Dos Santos Laine Patricia Costa LPC, Sampaio Larissa Andréia Ferreira LAF et al.

Aeromonas hydrophila is a major zoonotic bacterial pathogen responsible for haemorrhagic septicemia, substantial economic losses in aquaculture and increasing antimicrobial resistance among field isolates. It is also one of the main bacterial species associated with mortality outbreaks in pirapitinga, Piaractus brachypomus, culture in the Amazon region of Latin America. Therefore, this study evaluated the immunogenicity and protective efficacy of the first autogenous vaccine against A. hydrophila developed for P. brachypomus, formulated with or without a Montanide adjuvant. A total of 150 fish were vaccinated by intraperitoneal injection with a formalin-inactivated homologous bacterin and, at 35 days post-vaccination, challenged with a homologous strain of A. hydrophila at the median lethal dose (LD50). Following bacterial challenge, biological samples were collected at 24 h post-challenge, and survival was monitored for 15 days (50-day trial period). The vaccinated groups showed enhanced immune responses, characterized by increased ROS levels, lysozyme activity, agglutinating antibody titers and IgM levels, particularly in the fish vaccinated with the adjuvant. Haematological evaluation revealed lymphocytosis and, morphologically, lower lesion severity and preservation of renal architecture in vaccinated groups. In contrast, infected non-vaccinated fish exhibited leukopenia, tubular disorganization, intense mononuclear inflammatory infiltrates, glomerular alterations and lesions suggestive of tissue necrosis. These findings were reflected in enhanced protection following the bacterial challenge, with relative percent survival (RPS) values of 76.19% for fish vaccinated without the adjuvant and 85.71% for those vaccinated with the adjuvant. Overall, the autogenous vaccine was safe, immunogenic and provided effective protection against Aeromonas hydrophila infection in Piaractus brachypomus.

PMID 42567699
阅读全文 →
PubMedFrontiers in immunology2026-08-08

The promising cancer treatment approach in cancer immunotherapy: dendritic cell-based vaccines.

Wang Jingwen J, Jia Xibiao X, Zhang Yaxin Y, Wang Xiaoyu X et al.

Dendritic cells (DCs), as the most protent professional antigen-presenting cells (APCs), possess an exceptional capacity to initiate and modulate adaptive immune responses, rendering DC-based vaccines a highly promising approach in tumor immunotherapy. This review explores the biological properties of DCs, establishing a foundation for the rational development of DC vaccine. We further provide a comprehensive overview of current mainstream DC vaccine platforms, with analysis of three representative strategies: (i) DC vaccines loaded with tumor lysates; (ii) personalized neoantigen-pulsed DC vaccines; and (iii) DC-derived exosome vaccines, a rapidly emerging cell-free therapeutic modality. With respect to clinical translation, we summarize the outcomes of clinical trials conducted over the past five years, particularly targeting high-mortality malignancies. While the results are encouraging, the broad clinical application remains limited, posing several challenges, including functional heterogeneity of DCs and immunosuppressive tumor microenvironment, which need to be overcome. Combination strategies, such as DC vaccination paired with chemotherapy, radiotherapy or immune checkpoint blockade, are increasingly recognized as essential for enhancing therapeutic efficacy. With the sustainable progress in tumor immunobiology and advanced bioengineering in the future, the development of DC vaccines will be accelerated, offering novel therapeutic prospects for patients with refractory cancers.

PMID 42568543
阅读全文 →
PubMedVeterinary microbiology2026-08-08

Development and protection evaluation of a nanoparticle vaccine against transferrin-binding protein TbpBY167A of Glaesserella parasuis.

Chao Lumen L, Zhang Baoge B, Cai Yuchen Y, Zhu Chenguang C et al.

In this study, a novel nanoparticle vaccine that can efficiently display the protective antigen TbpBY167A of Glaesserella parasuis was constructed using the self-assembly property of the capsid (Cap) protein of porcine circovirus type 3 (PCV3). Traditional subunit vaccines against Glässer's disease often suffer from insufficient immunogenicity and suboptimal protective efficacy. The vaccine developed in the present study efficiently elicits both humoral and cellular immune responses via multivalent antigen display, leading to substantially enhanced overall adaptive immunity. This work therefore provides promising vaccine candidates with high safety and improved protective efficacy for the prevention and control of Glässer's disease.Monoclonal antibodies (MAbs) against TbpBY167A were generated using recombinant TbpBY167A protein expressed in E. coli and their epitope characteristics were identified and which can specifically react with TbpBY167A displayed on the surface of VLP (Virus-Like Particle). A recombinant baculovirus expressing the Cap protein of PCV3 fused with TbpBY167A at the N terminus was constructed. Guinea pigs were immunized with the nanoparticle vaccine and a conventional subunit vaccine (MBP-TbpBY167A), humoral immune responses, cytokine profiles, pathological changes, and protection rates after challenge were compared. One stable hybridoma cell line, designated 2D3, secreting MAbs against TbpBY167A was obtained, and its recognized epitope was mapped to a linear region spanning amino acids 269-275. Transmission electron microscopy confirmed that the Cap-TbpBY167A fusion protein self-assembled into homogeneous nanoparticles approximately 20 nm in diameter. Animal experiments showed that both the nanoparticle vaccine and the subunit vaccine elicited robust specific antibody responses and provided a 60% protection rate against lethal challenge. Notably, the nanoparticle vaccine group exhibited significantly milder histopathological lesions in the lungs and spleen compared with the subunit vaccine and challenge control groups. The Cap-TbpBY167A nanoparticle vaccine confers protection against lethal G. parasuis challenge and demonstrates less lesions of target organ pathology compared with the conventional subunit vaccine. The success of this study provides a novel antigen delivery strategy for the development of broad-spectrum vaccines against G. parasuis.

PMID 42567121
阅读全文 →
PubMedVaccine2026-08-08

A novel inactivated vaccine for cross-protection against Actinobacillus pleuropneumoniae in pigs.

Wei Wenbin W, Yang Ruicheng R, Wang Zesong Z, Feng Shifan S et al.

Actinobacillus pleuropneumoniae (APP) causes porcine contagious pleuropneumonia (PCP), a highly contagious respiratory disease that inflicts substantial economic losses to the global swine industry. Given the high serotypic diversity of APP and limited cross-protective efficacy of current vaccines, novel candidates are urgently needed. In contrast to commercial APP vaccines relying on formalin-inactivated native Apx toxoids, and to experimental antigens that frequently use truncated Apx fragments or proteins refolded from insoluble inclusion bodies, this study successfully expressed full-length, soluble recombinant ApxIA and ApxIIA. These novel recombinant antigens were combined with inactivated APP serotype 1 to construct an inactivated whole-cell subunit combination vaccine, designated BAA. Its protective efficacy against multiple APP serotypes was evaluated in a porcine challenge model. The BAA vaccine showed a favorable safety profile. Compared with control and toxin-free inactivated bacterial vaccine (Bac) groups, BAA-immunized pigs exhibited significantly higher levels of specific antibodies against ApxIA, ApxIIA, and bacterial antigens. After challenge with APP serotypes 1, 3, 5, and 7, BAA-vaccinated pigs achieved survival rates of 100%, 80%, 80%, and 100%, respectively, with milder clinical signs, reduced lung lesions, and significantly lower pulmonary bacterial loads than other groups. Histopathology confirmed markedly alleviated pulmonary pathology in BAA-vaccinated pigs. These results indicate that the BAA vaccine confers robust cross-protection against heterologous APP serotypes and is a promising candidate for PCP prevention.

PMID 42566982
阅读全文 →
PubMedJournal of vascular surgery cases and innovative techniques2026-08-08

Endovascular exclusion of an aortobronchial fistula 38 years following a blunt thoracic aortic injury.

Lian Tiffany T, Saldana-Ruiz Nallely N, Moore Jayden J, Pottinger Paul P et al.

Aortobronchial fistula is a rare but life-threatening cause of hemoptysis. We report the case of a 68-year-old man who developed an aortobronchial fistula 38 years after undergoing open repair of a blunt thoracic aortic injury from a plane crash. Initial thoracic endovascular aortic repair was performed covering the area of the previous open repair (zones III/IV) where fistulas typically form; however, persistent symptoms required extension with subsequent resolution of hemoptysis. Six years later, a suspected endograft infection following bronchitis was managed with antibiotics and chronic suppressive therapy. At 9-year follow-up, he remains stable. This case highlights the diagnostic challenges and late infection risk and supports thoracic endovascular aortic repair as a treatment option in selected high-risk patients.

PMID 42568660
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bronchitis vaccine